Anti-Hu CD99 Purified

Anti-Hu CD99 Purified
Regulatory status
RUO
Antigen
CD99
Clone
3B2/TA8
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-658-C100
In stock
143.00 USD

0.025 mg
11-658-C025
In stock
71.50 USD
Variant
0.1 mg
11-658-C100
In stock
143.00 USD

0.025 mg
11-658-C025
In stock
71.50 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG2a kappa
Specificity
The mouse monoclonal antibody 3B2/TA8 recognizes an extracellular epitope of CD99, an approximately 32 kDa sialoglycoprotein expressed on the surface of many cell types, with particularly strong expression on Ewing´s sarcoma and peripheral primitive neuroectodermal tumors. Within the hematopoietic system, CD99 is expressed on virtually all cell types except granulocytes.
Workshop
HLDA VI: WS Code T 6T-097, BP 534
Application details
Flow cytometry: Recommended dilution: 1-4 μg/ml.
Reactivity
Human
Immunogen
Human thymocytes
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
MIC2, HBA71, blood group Xg
Antigen description
CD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally CD99 was described as a human thymus leukemia antigen, an Ewing´s sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes.
Entrez Gene ID 4267
UniProt ID P14209
11-658_FC_Profil Značení
Flow cytometry surface staining pattern of human peripheral blood stained using anti-human CD99 (3B2/TA8) purified antibody (concentration in sample 2 μg/ml) GAM APC.
11-658_FC_Histogram
Separation of human lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD99 (3B2/TA8) purified antibody (concentration in sample 2 μg/ml) GAM APC.
11-658 MC
Mass cytometry (surface staining) of human peripheral blood cells (after separation using Ficoll-Paque density gradient centrifugation) with anti-human CD99 (3B2/TA8) Eu153. Gated on singlets.

Product specific references:

Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol. 2007 Aug;81(16):8666-76.
PubMed
Pickl WF, Pimentel-Muiños FX, Seed B: Lipid rafts and pseudotyping. J Virol. 2001 Aug;75(15):7175-83.
PubMed
Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G: Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood. 2009 Jan 8;113(2):347-57.
PubMed
Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stöckl J, Ebner C, Knapp W, Pickl WF: CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol. 1998 Nov 1;161(9):4671-8.
PubMed
Variant
0.1 mg
11-658-C100
In stock
143.00 USD

0.025 mg
11-658-C025
In stock
71.50 USD
Variant
0.1 mg
11-658-C100
In stock
143.00 USD

0.025 mg
11-658-C025
In stock
71.50 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-173
Reg. statusRUO
0.1 mg
115.50 USD